358 related articles for article (PubMed ID: 34147031)
1. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
[TBL] [Abstract][Full Text] [Related]
2. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.
Schweppe RE; Pozdeyev N; Pike LA; Korch C; Zhou Q; Sams SB; Sharma V; Pugazhenthi U; Raeburn C; Albuja-Cruz MB; Reigan P; LaBarbera DV; Landa I; Knauf JA; Fagin JA; Haugen BR
Mol Cancer Res; 2019 May; 17(5):1036-1048. PubMed ID: 30733375
[TBL] [Abstract][Full Text] [Related]
3. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
Yan P; Su Z; Zhang Z; Gao T
Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
[TBL] [Abstract][Full Text] [Related]
4. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
5. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
[TBL] [Abstract][Full Text] [Related]
6. A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.
Henderson YC; Mohamed ASR; Maniakas A; Chen Y; Powell RT; Peng S; Cardenas M; Williams MD; Bell D; Zafereo ME; Wang RJ; Scherer SE; Wheeler DA; Cabanillas ME; Hofmann MC; Johnson FM; Stephan CC; Sandulache V; Lai SY
J Clin Endocrinol Metab; 2021 Sep; 106(10):2962-2978. PubMed ID: 34120183
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
8. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
Pinto AT; Pojo M; Simões-Pereira J; Roque R; Saramago A; Roque L; Martins C; André S; Cabeçadas J; Leite V; Cavaco BM
Endocrine; 2019 Nov; 66(2):288-300. PubMed ID: 31368081
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
Wu H; Sun Y; Ye H; Yang S; Lee SL; de las Morenas A
Pathol Oncol Res; 2015 Jul; 21(3):695-701. PubMed ID: 25588542
[TBL] [Abstract][Full Text] [Related]
11. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
12. Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature.
Torrez M; Braunberger RC; Yilmaz E; Agarwal S
Pathol Res Pract; 2020 Oct; 216(10):153146. PubMed ID: 32853962
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
14. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
[No Abstract] [Full Text] [Related]
17. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study.
Deeken-Draisey A; Yang GY; Gao J; Alexiev BA
Hum Pathol; 2018 Dec; 82():140-148. PubMed ID: 30075157
[TBL] [Abstract][Full Text] [Related]
18. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
[TBL] [Abstract][Full Text] [Related]
19. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
20. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
[Next] [New Search]
